Disitamab vedotin: all 85 studies that test it
Page 1 of 1. Open to participants first (61), then studies with results posted, then the rest; newest registration first within each.
- Antibody-Drug Conjugate Plus Immunotherapy Versus Immunotherapy Plus Chemotherapy for Extensive Transurethrally Unresectable Very-High-Risk Non-Muscle-Invasive Bladder CancerNot yet recruitingNCT07879469Phase 2
- DV Plus Toripalimab With Cetirizine and Mecobalamin Pretreatment in Patients With Locally Advanced Unresectable or Metastatic Bladder CancerNot yet recruitingNCT07853053Phase 1
- A Single-Arm Study of Sintilimab and Disitamab Vedotin for Locally Advanced Eyelid Sebaceous Gland CarcinomaNot yet recruitingNCT07740993Phase 2
- Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder CancerRecruitingNCT07646145Phase 2
- HOPE-07-MIBC: Disitamab Vedotin Plus Immunotherapy vs Chemoimmunotherapy in Resectable HER2-Expressing MIBCNot yet recruitingNCT07608224Phase 2/3
- HERO-UTUC: Intravesical RC48 After RNU for HER2+ UTUCNot yet recruitingNCT07591805Phase 2
- Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal CanceNot yet recruitingNCT07509424Phase 2
- A Study of Disitamab Vedotin, Tunlametinib, and PD-1 Antibody for Advanced Gastric CancerNot yet recruitingNCT07507526Phase 2
- Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial CarcinomaRecruitingNCT07498907Phase 3
- Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II StudyRecruitingNCT07446452Phase 2
- RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC FailureNot yet recruitingNCT07366840Phase 2/3
- A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07315750Phase 3
- A Phase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder CancerNot yet recruitingNCT07279597Phase 2
- Conversion Therapy With RC48, Sintilimab, and SOX for HER2 1+/2+ Unresectable Gastric CancerRecruitingNCT07194005Phase 2
- Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract CancerNot yet recruitingNCT07159217Phase 2
- A Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin Combined With PD-1 Inhibitor and Radiotherapy as Bladder-preserving Therapy in Patients With Localized HER2-high Expressing Muscle-invasive Bladder Urothelial Carcinoma Following Maximal Transurethral ResectionNot yet recruitingNCT07142200Phase 2
- Efficacy and Safety of Disitamab Vedotin Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer：a Phase II StudyRecruitingNCT07093866Phase 2
- Disitamab Vedotin Combined With Ivonescimab in Cisplatin-Ineligible Muscle-Invasive Bladder CancerNot yet recruitingNCT06957561Phase 1/2
- A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction AdenocarcinomaNot yet recruitingNCT06944496Phase 3
- Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expressionRecruitingNCT06749860Phase 2
- Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung CancerRecruitingNCT06734182Phase 2
- First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)RecruitingNCT06730373Phase 2
- Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast CancerRecruitingNCT06649331Phase 2
- Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast CancerRecruitingNCT06642545Phase 2
- Neoadjuvant Therapy in Cervical CancerRecruitingNCT06558682Not applicable
- RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric CancerNot yet recruitingNCT06492317Phase 2
- A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid TumorsRecruitingNCT06417554Phase 1/2
- To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2RecruitingNCT06378242Phase 1/2
- Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical TrialRecruitingNCT06278870Phase 3
- Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate CancerRecruitingNCT06227156Phase 2
- DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line TherapyRecruitingNCT06221748Phase 2/3
- A Clinical Study of the Efficacy and Safety of Disitamab Vedotin in Combination With Radiotherapy for the Adjuvant Treatment of HER2 Overexpressing UTUC Patients With High Risk Factors for Recurrence After Radical SurgeryRecruitingNCT06210490Phase 2
- A Study of RC48-ADC Combined With Cadonilimab（AK104）in the Treatment of HER2-expression Locally Advanced or Metastatic Urothelial CarcinomaRecruitingNCT06178601Phase 2
- A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical CancerRecruitingNCT06155396Phase 2
- Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT06155383Phase 2
- Posterior-line Treatment With Disitamab Vedotin Plus PD-1 in Advanced HER2-low Expressing Gastric CancerRecruitingNCT06078982Phase 1
- A Study of RC48-ADC Combined With AK104 For Perioperative Treatment of Muscle-Invasive Bladder CancerRecruitingNCT06074484Phase 2
- Study of Disitamab Vedotin and Anlotinib in Patients With HR-Negative, HER2-Low-Expressing Metastatic Breast CancerNot yet recruitingNCT06000033Phase 2
- RC48-ADC in Adjuvant/Salvage Treatment of HER2 Positive Non-muscle-invasive Bladder CancerNot yet recruitingNCT05996952Phase 2
- RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBCRecruitingNCT05979740Phase 2
- RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 ExpressionRecruitingNCT05940896Phase 1
- A Study of RC48-ADC Combined with JS001 for Postoperative Adjuvant Treatment of Upper Tract Urothelial CarcinomaRecruitingNCT05917158Phase 2
- Disitamab Vedotin Combined With Radiotherapy for Bladder PreservationNot yet recruitingNCT05912205Phase 2
- Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)RecruitingNCT05904964Phase 3
- Efficacy and Safety of Tislelizumab in Combination With Disitamab-vedotin as Neoadjuvant Therapy for HER2-positive High-risk Upper Tract Urothelial Carcinoma (UTUC)RecruitingNCT05837806Phase 2
- RC48-ADC in HER2-low Advanced Breast CancerRecruitingNCT05831878Not applicable
- A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 MutationNot yet recruitingNCT05745740Phase 1/2
- Study of Disitamab Vedotin Combined With Gemcitabine in Neoadjuvant Treatment of Urothelial CarcinomaRecruitingNCT05723991Phase 4
- Disitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal CancerRecruitingNCT05493683Phase 2
- A Clinical Study of Disitamab Vedotin for Injection Combined With Penpulimab Injection in Neoadjuvant Therapy for Patients With HER2-expressing Cisplatin-intolerant cT2-T4aNxM0 Bladder Urothelial CarcinomaNot yet recruitingNCT05488353Phase 4
- RC48-ADC Combinatioed Envolizumab in Locally Advanced or Metastatic Biliary Tract Cancer With Positive HER-2Not yet recruitingNCT05417230Phase 2
- RC48-ADC Combined With S-1 for First-line Treatment of Advanced Gastroesophageal Adenocarcinoma With Moderate Expression of HER2RecruitingNCT05403242Phase 1/2
- An Open-label, Single-arm, Multicenter Phase II Clinical Study： Evaluating RC48-ADC Combined With Triplizumab in the Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder CancerNot yet recruitingNCT05356351Phase 2
- Pembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal CancerNot yet recruitingNCT05333809Phase 2
- A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial CarcinomaRecruitingNCT05302284Phase 3
- A Study of RC48-ADC Combined With JS001 For Perioperative Treatment of Muscle-Invasive Bladder CancerRecruitingNCT05297552Phase 2
- A Study of RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression)RecruitingNCT05135715Phase 2
- RC48 for Neoadjuvant Chemotherapy of HER2 Positive Breast CancerNot yet recruitingNCT05134519Phase 2
- A Study of RC48-ADC for the Treatment of HER2-expressing Gynecological MalignanciesRecruitingNCT04965519Phase 2
- A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-OverexpressionRecruitingNCT04714190Phase 3
- A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2RecruitingNCT04400695Phase 3
- A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast CancerActive, not recruitingNCT06966453Phase 1/2
- Disitamab Vedotin Plus Cadonilimab in Patients With HER2 Mutant Advanced or Metastatic Bile Duct AdenocarcinomaStatus unknownNCT06383533Phase 2
- Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder CancerActive, not recruitingNCT06187506Phase 2
- A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid TumorsActive, not recruitingNCT06157892Phase 2
- A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2Active, not recruitingNCT06003231Phase 2
- A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric CancerActive, not recruitingNCT05980481Phase 2/3
- Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2Active, not recruitingNCT05911295Phase 3
- RC48-ADC Combined With Bevacizumab in HER2-positive Advanced Colorectal CancerStatus unknownNCT05785325Phase 2
- Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast CancerStatus unknownNCT05726175Phase 2
- Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric CancerStatus unknownNCT05627414Phase 2
- Phase II Study of RC48-ADC in Treating Patients With Salivary Gland Tumors Expressing HER2Status unknownNCT05601401Phase 2
- First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric CancerActive, not recruitingNCT05586061Phase 2
- A Study of RC48-ADC for the Treatment of HER2-expression Metastatic Breast Cancer With Abnormal Activation of PAM PathwayStatus unknownNCT05331326Phase 2
- A Clinical Study of RC48-ADC Combined With Triplizumab For Treatment of Myometrial Invasive Bladder CancerStatus unknownNCT05016973Phase 2
- A Study of RC48-ADC in Subjects With HER2 Overexpressed Metastatic Biliary Tract CancerActive, not recruitingNCT04329429Phase 2
- A Study of RC48-ADC(Antibody Drug Conjugate) and JS001 to Evaluate the Safety and Pharmacokinetics of Subjects With Locally Advanced or Metastatic Urothelial CancerStatus unknownNCT04264936Phase 1/2
- A Study of RC48-ADC in Subjects With HER2-negative Locally Advanced or Metastatic Urothelial CancerCompletedNCT04073602Phase 2
- A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial CancerCompletedNCT03809013Phase 2
- A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer Subjects With the Overexpression of HER2CompletedNCT03556345Phase 2
- A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial CancerCompletedNCT03507166Phase 2
- A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver MetastasesActive, not recruitingNCT03500380Phase 2/3
- A Study of RC48-ADC in Subjects With Advanced Breast CancerCompletedNCT03052634Phase 1/2
- Study of RC48-ADC Administered Intravenously to Subjects With HER2-Positive in Advanced Malignant Solid TumorsCompletedNCT02881190Phase 1
- A Study of RC48-ADC in Subjects With HER2-Positive Advanced Malignant Solid TumorsCompletedNCT02881138Phase 1